GEP20267899B - Actrii proteins and uses thereof - Google Patents

Actrii proteins and uses thereof

Info

Publication number
GEP20267899B
GEP20267899B GEAP202416461A GEAP2024016461A GEP20267899B GE P20267899 B GEP20267899 B GE P20267899B GE AP202416461 A GEAP202416461 A GE AP202416461A GE AP2024016461 A GEAP2024016461 A GE AP2024016461A GE P20267899 B GEP20267899 B GE P20267899B
Authority
GE
Georgia
Prior art keywords
actrii proteins
actrii
proteins
telangiectasia
abstract
Prior art date
Application number
GEAP202416461A
Other languages
English (en)
Georgian (ka)
Inventor
Oliveira Pena Janethe De
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of GEAP202416461A publication Critical patent/GEAP202416461A/en
Publication of GEP20267899B publication Critical patent/GEP20267899B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
GEAP202416461A 2021-07-19 2022-07-18 Actrii proteins and uses thereof GEP20267899B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163223265P 2021-07-19 2021-07-19

Publications (2)

Publication Number Publication Date
GEAP202416461A GEAP202416461A (en) 2024-04-25
GEP20267899B true GEP20267899B (en) 2026-06-10

Family

ID=84979535

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP202416461A GEP20267899B (en) 2021-07-19 2022-07-18 Actrii proteins and uses thereof

Country Status (18)

Country Link
US (1) US20240327494A1 (cg-RX-API-DMAC7.html)
EP (1) EP4373577A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024526820A (cg-RX-API-DMAC7.html)
KR (1) KR20240049857A (cg-RX-API-DMAC7.html)
CN (1) CN117957014A (cg-RX-API-DMAC7.html)
AU (1) AU2022316103A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225613A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000151A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024001551A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240061A (cg-RX-API-DMAC7.html)
DO (2) DOP2024000016A (cg-RX-API-DMAC7.html)
EC (1) ECSP24012819A (cg-RX-API-DMAC7.html)
GE (1) GEP20267899B (cg-RX-API-DMAC7.html)
IL (1) IL310141A (cg-RX-API-DMAC7.html)
JO (1) JOP20240010A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024000829A (cg-RX-API-DMAC7.html)
PE (1) PE20240777A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023003815A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4121078A4 (en) 2020-03-20 2024-08-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI745271B (zh) * 2014-05-19 2021-11-11 美商西建公司 全身紅斑性狼瘡之治療
WO2016146573A1 (en) * 2015-03-13 2016-09-22 Repoceuticals Aps Melatonin for preventing and treating radiation cystitis
JP7072507B2 (ja) * 2015-11-23 2022-05-20 アクセルロン ファーマ インコーポレイテッド 眼の障害を処置するための方法
PL4218804T3 (pl) * 2016-06-13 2026-05-25 Scholar Rock, Inc. Stosowanie inhibitorów miostatyny i terapii skojarzonych
AU2017296040C1 (en) * 2016-07-15 2023-06-22 Acceleron Pharma Inc. Compositions and methods for treating pulmonary hypertension

Also Published As

Publication number Publication date
DOP2024000016A (es) 2024-06-16
GEAP202416461A (en) 2024-04-25
CO2024001551A2 (es) 2024-03-07
AU2022316103A1 (en) 2024-02-08
US20240327494A1 (en) 2024-10-03
MX2024000829A (es) 2024-04-12
WO2023003815A1 (en) 2023-01-26
EP4373577A4 (en) 2025-05-14
CR20240061A (es) 2024-05-02
CN117957014A (zh) 2024-04-30
JP2024526820A (ja) 2024-07-19
CL2024000151A1 (es) 2024-08-09
DOP2026000113A (es) 2026-07-15
WO2023003815A9 (en) 2023-05-11
IL310141A (en) 2024-03-01
JOP20240010A1 (ar) 2024-01-18
ECSP24012819A (es) 2024-03-01
CA3225613A1 (en) 2023-01-26
KR20240049857A (ko) 2024-04-17
PE20240777A1 (es) 2024-04-17
EP4373577A1 (en) 2024-05-29